Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H

Gene Therapy

Volumn 21, Issue 6, 2014, Pages 575-584

  Inaguma, Y ^a   Akahori, Y ^b   Murayama, Y ^a   Shiraishi, K ^c   Tsuzuki Iba, S ^a   Endoh, A ^a   Tsujikawa, J ^a   Demachi Okamura, A ^c   Hiramatsu, K ^c   Saji, H ^d   Yamamoto, Y ^a   Yamamoto, N ^b   Nishimura, Y ^e   Takahashi, T ^c   Kuzushima, K ^c   Emi, N ^a   Akatsuka, Y ^a,c  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d Japanese Red Cross Kanto Koshinetsu Block Blood Center   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPITOPE; HLA A2 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MINOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN HA 1H; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TETRAMER; UNCLASSIFIED DRUG; CD8 ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; ANTIGEN; CD3 ANTIGEN; CYTOKINE; RECOMBINANT ANTIGEN; RECOMBINANT HLA A2 ANTIGEN;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEX FORMATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TRANSGENE; ANIMAL; ANTIBODY SPECIFICITY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; TRANSGENIC MOUSE; BINDING AFFINITY; CELL CLONE; CELL DENSITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE CONSTRUCT; IN VITRO STUDY; IN VIVO STUDY; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD8; BASE SEQUENCE; BETA 2-MICROGLOBULIN; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; HLA-A2 ANTIGEN; HUMANS; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84902086485     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.30     Document Type: Article

References (47)

1. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donorleukocyte transfusions for treatment of recurrent chronic myelogenous leukemiain marrow transplant patients. Blood 1990; 76 (12): 2462-2465.
2. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der HoornMA et al. Hematopoiesis-Res.tricted minor histocompatibility antigens HA-1-orHA-2-specific T cells can induce complete remissions of relapsed leukemia.Proc Natl Acad Sci USA 2003; 100: 2742-2747.
3. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL et al.The minor histocompatibility antigen HA-1: a diallelic gene with a single aminoacid polymorphism. Science 1998; 279: 1054-1057.
4. Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, van der Hoorn MA, Goulmy E et al. Redirection of antileukemic reactivity of peripheral T lymphocytesusing gene transfer of minor histocompatibility antigen HA-2-specific T-cellreceptor complexes expRes.sing a conserved alpha joining region. Blood 2003;102: 3530-3540.
5. Ochi T, Fujiwara H, Okamoto S, An J, Nagai K, Shirakata T et al. Novel adoptiveT-cell immunoTher.apy using a WT1-specific TCR vector encoding silencers forendogenous TCRs shows marked antileukemia reactivity and safety. Blood 2011;118: 1495-1503.
6. Udyavar A, Geiger TL. Rebalancing immune specificity and function in cancer byT-cell receptor gene Ther.apy. Arch Immunol Ther. Exp 2010; 58: 335-346.
7. Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A et al.Lethal graft-versus-host disease in mouse models of T cell receptor gene Ther.apy.Nat Med. 2010; 16: 565-570.
8. Heemskerk MH, Hagedoorn RS, van derHoornMA, van der Veken LT, HoogeboomM, Kester MG et al. Efficiency of T-cell receptor expRes.sion in dual-specific T cells iscontrolled by the intrinsic qualities of the TCR chains within the TCR-CD3complex. Blood 2007; 109: 235-243.
9. van Loenen MM, de Boer R, Amir AL, Hagedoorn RS, Volbeda GL, Willemze R et al.Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc NatlAcad Sci USA 2010; 107: 10972-10977.
10. van der Veken LT, Hagedoorn RS, van Loenen MM, Willemze R, Falkenburg JH, Heemskerk MH. Alphabeta T-cell receptor engineered gammadelta T cellsMed.iate effective antileukemic reactivity. Cancer Res. 2006; 66: 3331-3337.
11. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S et al. A foundation for universalT-cell based immunoTher.apy: T cells engineered to expRes.s a CD19-specificchimeric-antigen-receptor and eliminate expRes.sion of endogenous TCR. Blood2012; 119: 5697-5705.
12. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation byantibody-like immunoreceptors: increase in affinity of the single-chain fragmentdomain above thRes.hold does not increase T cell activation against antigenpositivetarget cells but decreases selectivity. J Immunol 2004; 173: 7647-7653.
13. Dotti G, Savoldo B, Brenner M. Fifteen years of gene Ther.apy based on chimericantigen receptors: "are we nearly Ther.e yet?". Human Gene Ther. 2009; 20: 1229-1239.
14. Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R et al.Chimeric antigen receptor-engineered T cells for immunoTher.apy of cancer.J BioMed. Biotechnol 2010; 2010: 956304.
15. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineeredT cells. Trends Biotechnol 2011; 29: 550-557.
16. Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E et al.Rational development of high-affinity T-cell receptor-like antibodies. Proc NatlAcad Sci USA 2009; 106: 5784-5788.
17. Weidanz JA, Hawkins O, Verma B, Hildebrand WH. TCR-like biomolecules targetpeptide/MHC Class I complexes on the surface of infected and cancerous cells.Int Rev. Immunol 2011; 30: 328-340.
18. Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J et al. An anti-PR1/HLA-A2T-cell receptor-like antibody Med.iates complement-dependent cytotoxicityagainst acute myeloid leukemia progenitor cells. Blood 2011; 117: 4262-4272.
19. Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR. Directselection of a human antibody fragment directed against the tumor T-cell epitopeHLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc Natl Acad SciUSA 2000; 97: 7969-7974.
20. Cohen CJ, Sarig O, Yamano Y, Tomaru U, Jacobson S, Reiter Y. Direct phenotypicanalysis of human MHC class I antigen pRes.entation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHCRes.trictedhuman recombinant antibodies. J Immunol 2003; 170: 4349-4361.
21. Bernardeau K, Gouard S, David G, Ruellan AL, Devys A, Barbet J et al. Assessmentof CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody.Eur. J Immunol 2005; 35: 2864-2875.
22. Weidanz JA, Nguyen T, Woodburn T, Neethling FA, Chiriva-Internati M, HildebrandWH et al. Levels of specific peptide-HLA class I complex predicts tumor cellsusceptibility to CTL killing. J Immunol 2006; 177: 5088-5097.
23. Andersen PS, Stryhn A, Hansen BE, Fugger L, Engberg J, Buus S. A recombinantantibody with the antigen-specific, major histocompatibility complex-Res.trictedspecificity of T cells. Proc Natl Acad Sci USA 1996; 93: 1820-1824.
24. Krogsgaard M, Wucherpfennig KW, Cannella B, Hansen BE, Svejgaard A, Pyrdol Jet al. Visualization of myelin basic protein (MBP) T cell epitopes in multiplesclerosis lesions using a monoclonal antibody specific for the human histocompatibilityleukocyte antigen (HLA)-DR2-MBP 85-99 complex. J Exp Med. 2000;191: 1395-1412.
25. Miyazaki M, Akatsuka Y, Nishida T, Fujii N, Hiraki A, Ikeda K et al. Potential limitationsin using minor histocompatibility antigen-specific cytotoxic T cells fortargeting solid tumor cells. Clin Immunol 2003; 107: 198-201.
26. Thomas S, Xue SA, Bangham CR, Jakobsen BK, Morris EC, Stauss HJ. Human T cellsexpRes.sing affinity-matured TCR display accelerated Res.ponses but fail to recognizelow density of MHC-peptide antigen. Blood 2011; 118: 319-329.
27. Poncelet P, Carayon P. Cytofluorometric quantification of cell-surface antigens byindirect immunofluoRes.cence using monoclonal antibodies. J Immunol Methods1985; 85: 65-74.
28. Wang L, Abbasi F, Gaigalas AK, Vogt RF, Marti GE. Comparison of fluoRes.cein andphycoerythrin conjugates for quantifying CD20 expRes.sion on normal and leukemicB-cells. Cytometry B Clin Cytometry 2006; 70: 410-415.
29. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D et al. Chimericreceptors containing CD137 signal transduction domainsMed.iate enhanced survivalof T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009; 17: 1453-1464.
30. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA et al.Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.J ImmunoTher. 2009; 32: 689-702.
31. Kesmir C, Nussbaum AK, Schild H, Detours V, Brunak S. Predictionof proteasome cleavage motifs by nEur.al networks. Protein Eng 2002; 15:287-296.
32. Parker KC, Bednarek MA, Coligan JE. SChem.e for ranking potential HLA-A2 bindingpeptides based on independent binding of individual peptide side-chains.J Immunol 1994; 152: 163-175.
33. Laugel B, Cole DK, Clement M, Wooldridge L, Price DA, Sewell AK. The multipleroles of the CD8 coreceptor in T cell biology: opportunities for theselective modulation of self-reactive cytotoxic T cells. J Leuk Biol 2011; 90:1089-1099.
34. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N et al.Targeted T-cell Ther.apy for human leukemia: cytotoxic T lymphocytes specific fora peptide derived from proteinase 3 preferentially lyse human myeloidleukemia cells. Blood 1996; 88: 2450-2457.
35. Valitutti S. The serial engagement model 17 years after: from TCR triggering toimmunoTher.apy. Front Immunol 2012; 3: 272.
36. van der Merwe PA, Davis SJ. Molecular interactions Med.iating T cell antigenrecognition. Annu Rev. Immunol 2003; 21: 659-684.
37. Firat H, Garcia-Pons F, Tourdot S, Pascolo S, Scardino A, Garcia Z et al. H-2 class Iknockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinicalevaluation of antitumor immunoTher.apeutic strategies. Eur. J Immunol 1999; 29:3112-3121.
38. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-Res.tricted education and cytolytic activity of CD8(+) T lymphocytes from beta2microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m doubleknockout mice. J Exp Med. 1997; 185: 2043-2051.
39. Kondo E, Topp MS, Kiem HP, Obata Y, Morishima Y, Kuzushima K et al. Efficientgeneration of antigen-specific cytotoxic T cells using retrovirally transducedCD40-activated B cells. J Immunol 2002; 169: 2164-2171.
40. Torikai H, Akatsuka Y, Miyazaki M, Warren 3rd EH, Oba T, Tsujimura K et al. A novelHLA-A*3303-Res.tricted minor histocompatibility antigen encoded by an unconventionalopen reading frame of human TMSB4Y gene. J Immunol 2004; 173:7046-7054.
41. Kuzushima K, Hayashi N, Kudoh A, Akatsuka Y, Tsujimura K, Morishima Y et al.Tetramer-assisted identification and characterization of epitopes recognized byHLA A*2402-Res.tricted Epstein-Barr virus-specific CD8+ T cells. Blood 2003; 101:1460-1468.
42. Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T cellepitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1(LMP1): evidence for HLA A2 supertype-Res.tricted immune recognition of EBVinfectedcells by LMP1-specific cytotoxic T lymphocytes. Eur. J Immunol 1998; 28:451-458.
43. Higo-Moriguchi K, Akahori Y, Iba Y, Kurosawa Y, Taniguchi K. Isolation of humanmonoclonal antibodies that neutralize human rotavirus. J Virol 2004; 78:3325-3332.
44. Cohen CJ, Denkberg G, Lev A, Epel M, Reiter Y. Recombinant antibodies withMHC-Res.tricted, peptide-specific, T-cell receptor-like specificity: new tools to studyantigen pRes.entation and TCR-peptide-MHC interactions. J Mol Recognit 2003; 16:324-332.
45. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G.By-passing immunization. Human antibodies from V-gene libraries displayedon phage. J Mol Biol 1991; 222: 581-597.
46. Iba Y, Ito W, Kurosawa Y. ExpRes.sion vectors for the introduction of highlydiverged sequences into the six complementarity-determining regions of anantibody. Gene 1997; 194: 35-46.
47. Lee JT, Yu SS, Han E, Kim S, Kim S. Engineering the splice acceptor for improvedgene expRes.sion and viral titer in an MLV-based retroviral vector. Gene Ther. 2004;11: 94-99.